Mesenchymal stromal cells in hematopoietic cell transplantation

Andre J. Burnham, Lisa P. Daley-Bauer, and Edwin M. Horwitz
Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA; and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA

Mesenchymal stromal cells (MSCs) are widely recognized to possess potent immunomodulatory activity, as well as to stimulate repair and regeneration of diseased or damaged tissue. These fundamental properties suggest important applications in hematopoietic cell transplantation. Although the mechanisms of therapeutic activity in vivo are yet to be fully elucidated, MSCs seem to suppress lymphocytes by paracrine mechanisms, including secreted mediators and metabolic modulators. Most recently, host macrophage engulfment of apoptotic MSCs has emerged as an important contributor to the immune suppressive microenvironment. Although bone marrow–derived MSCs are the most commonly studied, the tissue source of MSCs may be a critical determinant of immunomodulatory function. The key application of MSC therapy in hematopoietic cell transplantation is to prevent or treat graft-versus-host disease (GVHD). The pathogenesis of GVHD reveals multiple potential targets. Moreover, the recently proposed concept of tissue tolerance suggests a new possible mechanism of MSC therapy for GVHD. Beyond GVHD, MSCs may facilitate hematopoietic stem cell engraftment, which could gain greater importance with increasing use of haploidentical transplantation. Despite many challenges and much doubt, commercial MSC products for pediatric steroid-refractory GVHD have been licensed in Japan, conditionally licensed in Canada and New Zealand, and have been recommended for approval by an FDA Advisory Committee in the United States. Here, we review key historical data in the context of the most salient recent findings to present the current state of MSCs as adjunct cell therapy in hematopoietic cell transplantation.

Introduction

Human mesenchymal stromal cells (MSCs), previously referred to as mesenchymal stem cells, were first described in bone marrow in 1968.1,2 Since then, MSCs have been isolated from a striking array of fetal and adult tissues, suggesting that they may reside in virtually every tissue in the human body.3-9 Depending on the tissue of origin and the ex vivo expansion protocol, MSCs have been shown to exhibit a variety of morphological and physiological characteristics. This variability, as well as considerable in vitro plasticity, has confounded efforts to assign a precise phenotype to define the identity of MSCs.10 Given the ability of MSCs to differentiate into osteoblasts, chondrocytes, and adipocytes in culture, many investigators have proposed that MSCs are stem cells or progenitors that give rise to specialized mesodermal cell lineages during development or throughout the process of tissue regeneration.11-15 However, there is a conspicuous lack of evidence that MSCs physiologically perform this function in vivo. Indeed, MSCs present in some tissues could be multipotent and directly perform stem cell–like functions, although in vivo data are lacking. It is more likely, however, that MSCs indirectly facilitate endogenous cellular mechanisms that result in tissue repair and regeneration, giving the impression of stem cell–like activity.16 Regardless of the mechanism, MSCs have been shown to promote tissue repair in various damaged or inflamed sites in the laboratory and in clinic trials.17
MSCs are also known to exert strong immunosuppressive activity on the adaptive and innate immune systems.18-21 MSCs have been reported to inhibit proliferation of T and B lymphocytes via contact-dependent and secretory mechanisms and to promote anti-inflammatory pathways in vitro and in vivo.19,22-24 As a result, the therapeutic properties of MSCs in combating various human diseases that are impacted by the immune system, such as graft-versus-host disease (GVHD), have been examined in many preclinical studies and several clinical trials.10 Although clinical trials have generated mixed results in treating GVHD, Mesoblast Limited has recently produced promising results in a clinical trial for their off-the-shelf MSC therapy RYONCIL (remestemcel-L). 25

Indeed, the immunomodulatory properties of MSCs present clinical advantages in treating and preventing GVHD, as well as promoting tissue repair and engraftment during hematopoietic cell transplantation (HCT). In this review, we describe in vitro, in vivo, and clinical studies in which MSCs have been applied as immunomodulatory cell therapies during HCT to prevent and treat GVHD, repair damaged tissue, and facilitate hematopoietic stem cell engraftment (Figure 1).

**Ex vivo preparation of MSCs**

MSCs are obtained for research and clinical studies from an array of tissue sources. Viable MSCs have been isolated from bone marrow, adipose tissue, amniotic membrane and fluid, placental and fetal tissues, umbilical cord tissues, endometrium, blood, and synovial fluid. However, MSCs isolated from bone marrow are most commonly studied clinically.10 In addition, there is increasing evidence that stromal cells derived from decidua placental tissues may have more immunosuppressive activity and therapeutic potential than bone marrow–derived MSCs (BM-MSCs).26-29 BM-MSCs and MSCs collected from various other tissues are more effectively isolated via a Ficoll density gradient by plating the Ficoll-purified suspension in a culture dish, washing off adherent hematopoietic cells, and collecting the remaining adherent spindle-shaped cells.9,30-32 The efficacy of other MSC-isolation methods, including a bone marrow filtration system, is also being investigated.33

Upon isolation, MSCs must be expanded in culture ex vivo, because cell numbers are very limited in human tissues. MSCs may be effectively cultured in several media, although Dulbecco’s modified Eagle media and αMEM are the most common. Although serum-free media for tissue culture of MSCs is under development, current protocols require some serum supplementation. For ex vivo expansion of MSCs in animal studies, fetal bovine serum or human platelet lysate may be used.10 For preclinical and clinical applications, human platelet lysate may be more suitable to avoid xenoprotein exposure.34

The impacts of cryopreservation and freeze-thaw cycles on MSC immunomodulatory activity remain speculative.35,36 Previous studies have demonstrated that a freeze-thaw cycle may reduce MSC immunosuppressive activity in vitro, in vivo, and in clinical studies.35-36 However, other studies have shown in vitro and in vivo immunosuppressive activity to be maintained after thawing cryopreserved MSCs.39,40 A multitude of factors, including passage number, tissue source, thawing conditions, cell culture media used, biological activity, and disease application, likely contribute to the efficacy of cryopreserved MSCs compared with cells maintained in culture. Most importantly, a randomized study comparing the efficacy of freshly prepared and cryopreserved/thawed MSCs has not been reported.

**Immunomodulatory properties of MSCs**

The immunomodulatory properties of MSCs have been extensively investigated in vitro and in vivo (Table 1), providing significant implications toward applying MSCs to HCT. These immunomodulatory properties can effectively regulate the adaptive and innate immune responses, although additional research is required to understand which mechanisms occur in vivo. Focusing on T cells, MSCs have demonstrated the ability to suppress the proliferation of CD4+ and CD8+ activated T cells and inhibit the differentiation of CD8+ cytotoxic T cells.22,23 Because these suppressive effects have been observed in cocultures when MSCs are separated from peripheral blood mononuclear cells via a Transwell membrane, MSC-modulated lymphocyte suppression seems to be due to...
paracrine mechanisms, including secreted mediators (eg, transforming growth factor-β, hepatocyte growth factor, prostaglandin E2), as well as metabolic activity (eg, indoleamine 2,3-dioxygenase). Interestingly, it has been shown that MSCs only display suppressive activity against T lymphocytes when first primed with interferon-γ (IFN-γ), suggesting that this is the “active form” of MSCs for T-cell suppression. The exact mechanism(s) of action of MSC-induced T-cell suppression in vivo is poorly understood for GVHD or any given clinical indication. Most likely, not all immune-suppressive activity of MSCs is relevant to every clinical setting. The most recognized current concepts are that MSCs inhibit proliferation by arresting T cells in the G0/G1 phases of the cell cycle and perhaps recognized current concepts are that MSCs inhibit proliferation by arresting T cells in the G0/G1 phases of the cell cycle and perhaps

MSCs have also been implicated in the suppression of B lymphocytes. For instance, after being activated with anti-CD40L and interleukin-4 (IL-4), B-cell proliferation of murine MSCs is suppressed. Likewise, human MSCs consistently suppress B-cell proliferation in vitro in the presence of anti-immunoglobulin antibodies, soluble CD40L, and various other cytokines (eg, IFN-γ). Although B cells contribute to the pathogenesis of GVHD, it is not known whether MSCs impact this particular B-cell activity.

MSCs interact with the innate immune system, specifically by signaling with monocytes and macrophages to promote pro- or anti-inflammatory pathways and repair damaged tissues. For example, upon being primed by proinflammatory cytokines (such as IFN-γ, tumor necrosis factor, and Toll-like receptor ligands) or in the presence of monocytes in coculture, MSCs become immunosuppressive and promote the polarization of M2 macrophages. Additionally, MSCs can facilitate wound and tissue repair by recruiting monocytes and macrophages to inflamed sites through the secretion of chemokine ligands and other cytokines. Thus, a component of MSC-mediated action against GVHD could be attributed to the polarization of M2 macrophages, which reduce inflammation and promote wound healing.

There is also evidence that inactive (apoptotic) MSCs and MSCs engulfed by phagocytes (eg, monocytes) or inactivated via recipient cytotoxic cells promote host immunosuppressive mechanisms in vitro and in mouse models. In fact, Galleu et al recently reported that only GVHD patients with high cytotoxic activity against MSCs responded to MSC infusions, suggesting that MSC cell death pathways stimulated by the innate immune response may contribute to MSC-mediated immunosuppression.

### Prevention and treatment of GVHD

#### Overview of GVHD pathogenesis

Although detailed mechanisms of GVHD have been described, Ferrara and colleagues proposed what has become the classic 3-stage conceptualization of the pathogenesis of acute GVHD (aGVHD). In stage 1, the conditioning regimen, radiation, and/or chemotherapy injures nonhematopoietic tissue, resulting in inflammation and secretion of inflammatory cytokines. Stage 2 ensues after the hematopoietic graft has been infused when the adoptively transferred donor T cells are activated by host antigen-presenting cells, which is potently promoted by the inflammatory cytokines resulting from the injured tissues. In stage 3, activated donor T cells target host tissue and initiate alloreactive cytotoxic mechanisms.

This 3-stage schema can illustrate the opportunities for IV-infused MSC prophylaxis and treatment of aGVHD (Figure 2). In stage 1, MSCs may migrate to sites of inflammation and limit tissue injury and hasten healing by their tissue-regeneration activity. In stage 2, MSCs may traffic to sites of alloactivation and inhibit the proliferation of activated T cells. In stage 3, MSCs may migrate to sites of donor T-cell host-tissue interaction and inhibit the immune response. For established GVHD, MSCs could migrate to the sites of host tissue, target and suppress alloreactive T-cell cytotoxicity, and promote tissue healing.

Although less understood than aGVHD, chronic GVHD (cGVHD) is proposed to occur as a result of thymic damage and impaired T-cell–negative selection, poor regulatory T-cell function, production of autoantibodies, and probiotic lesions. Although MSCs have been studied as therapy for cGVHD, the underpinnings of a successful therapy are less certain.

### Table 1. A summary and comparison of proposed immunomodulatory mechanisms of MSCs in studies reviewed herein

| Cell/mechanism | Immune effect | Proposed MOA | Model | Reference |
|---------------|---------------|--------------|-------|-----------|
| **Adaptive immunity** | | | | |
| CD4⁺/CD8⁺ suppression | T-cell proliferation, survival | IFN-γ priming/IDO metabolism | In vitro/vivo | 22,23 |
| CD4⁺/CD8⁺ death | T-cell apoptosis? | IFN-γ priming/IDO metabolism | In vitro | 47 |
| T cell–Treg polarization | Inflammation? | IFN-γ/cytokine/paracrine | In vitro | 48 |
| B-cell suppression | B proliferation | IFN-γ/cytokine/paracrine | In vitro | 43,44 |
| **Innate immunity** | | | | |
| Polarize M2 macrophages | Inflammation | Monocyte/IFN-γ MSC priming | In vitro | 19,21,53 |
| Macrophage recruiting | Tissue repair | Chemotaxis to damaged tissue | In vitro/vivo | 19,24,54 |
| Monocyte recruiting | Tissue repair | Chemotaxis to damaged tissue | In vitro/vivo | 19,24,54 |
| Apoptotic MSCs | Immunosuppression | Phagocytic-induced suppression | In vitro/vivo | 55-57 |

IDO, indoleamine 2,3-dioxygenase; MOA, mechanism of action; Treg, regulatory T cell; ↑, increased; ↓, decreased.
MSCs as immunosuppressive treatments for GVHD

Given that interest in clinical applications began with hematologists who focus on HCT, it is not surprising that GVHD has commanded considerable attention. In preclinical animal models, MSCs isolated from different sources and/or cultured under different conditions have been shown to have varying effects on GVHD. In a murine study, C57BL/6 and BALB/c mice were injected with BM-MSCs and T cells in a bone marrow transplant at a ratio previously demonstrated effective suppression of T-cell proliferation in vitro, although the transplant did not effectively reduce GVHD or increase survival. In a more recent study, human BM-MSCs significantly reduced GVHD and increased survival in irradiated B6D2F1 mice. Polchert et al were the first to show that when murine BM-MSC infusions are activated with IFN-γ, survival is increased, and GVHD may be prevented and treated.

Weekly doses of MSCs isolated from human umbilical cord tissue were recently shown to prevent, but not reduce, GVHD in peripheral blood mononucleocyte–transplanted NOD/SCID mice. Despite these variations observed between animal studies, a recent meta-analysis of 50 studies demonstrated robust prophylaxis of clinical aGVHD and increased survival in rat and murine allogeneic HCT models. Interestingly, cell dose and administration time were not significant predictors of aGVHD-associated mortality, whereas MSC source showed strong correlations with treatment outcome; of note, BM-MSCs and umbilical cord blood–derived MSCs demonstrated high efficacy, whereas adipose-derived MSCs did not differ from control groups.

Indeed, preclinical animal studies have presented mixed results, underscoring the importance of appreciating the nuances of a specific model and experimental conditions. A consistent finding among animal and clinical studies is that MSC infusions seem to be safe, laying the foundation for the plethora of clinical trials. With regard to clinical efficacy, MSCs applied as adjunct therapies for aGVHD in the context of HCT have also generated mixed results. In a recent systematic review and meta-analysis of 9 studies and 309 patients, Kallekleiv et al reported that MSCs did not have a significant effect on aGVHD. However, other meta-analyses show that MSCs are promising candidates for treatment of aGVHD. For example, Chen et al proposed that patient age, skin involvement, lower-grade disease, and infusion number are significant prognostic factors for the efficacy of MSC treatments for steroid-refractory aGVHD. Given that there is high heterogeneity in clinical study design, and few randomized clinical trials that meet inclusion criteria for many systematic reviews, meta-analyses on the topic of MSC-based therapies for GVHD should be interpreted with caution.

Le Blanc et al were the first to demonstrate BM-MSCs as an effective treatment of GVHD; a 9-year-old boy diagnosed with grade IV refractory aGVHD in the liver and gut following unrelated donor allogeneic HCT responded rapidly to treatment with maternal MSCs. Interestingly, these investigators did not have preclinical animal data prior to treating this patient. In 2008, these investigators reported a phase 2 clinical study applying ex vivo–expanded BM-MSCs as a treatment for severe refractory aGVHD. In this work, 55 patients were administered 1 to 5 doses of MSCs donated from HLA-identical sibling donors, haploidentical donors, or third-party HLA-mismatched donors. No MSC-related toxicity was associated with these infusions; 30 patients demonstrated a complete response to treatment, including increased survival, and 9 showed improved symptoms. Response rate was not correlated with donor
HLA match status, suggesting that MSCs expanded from a third-party donor are equally effective as MSCs donated by HLA-compatible donors. More recently, Salmenniemi et al surveyed 30 patients (22 adults and 8 children) diagnosed with steroid-refractory aGVHD or cGVHD, following treatment with 6 weekly or biweekly doses (2 × 10^6 cells per kg) of third-party BM-MSCs expanded in human platelet lysate. On day +28 postinfusion, 62% of aGVHD patients had successfully responded to treatment. Four of the 22 adult patients suffered from cGVHD and did not respond to treatment, 3 of whom had died 3 months into the study. Although the response rate did not differ statistically between adult (50%) and pediatric (88%) patients experiencing aGVHD, survival was significantly higher (P = .003) in children (88%) than in adults (22%) at median follow-up on day +767. In 2016, a phase 2/3 clinical trial for grade 3/4 steroid-refractory aGVHD reported 24% and 36% complete responses and partial responses, respectively, at 4 weeks postinfusion of BM-MSCs and ~80% complete responses by week 8.

The first large-scale industry phase 3 randomized clinical trial (NCT00366145; Prochymal [remestemcel-L]) for allogeneic third-party donor BM-MSCs as a treatment for refractory aGVHD was reported in 2009 by Osiris Therapeutics. Overall, patients suffering from steroid-refractory aGVHD did not show a statistically significant improvement following infusion of the cell therapy compared with placebo; however, the response in children on day +28 was clinically interesting, but the study was not powered to prove a benefit in this subgroup. Importantly, this was the first study to suggest that MSCs may be more effective in children. Despite an array of mixed results reported since this trial began, other phase 3 studies have resulted in clinical approval of commercial MSC products for the treatment of aGVHD in Japan (TEMCELL), as well as conditional approval for pediatric aGVHD in Canada and New Zealand (Prochymal). Of note, Mesoblast Limited obtained Prochymal from Osiris Therapeutics, has rebranded the MSC product [remestemcel-L] as RYONCIL, and continues to develop it in clinical trials. In a recent United States phase 3 clinical trial (NCT02336230) reported in March 2020 by Mesoblast Limited, RYONCIL/remestemcel-L was infused IV into 55 children with steroid-refractory aGVHD at a dose of 2 × 10^6 MSCs/kg twice a week for 4 weeks. It resulted in a day +28 overall response of 69.1%, as well as 74.5% and 69.5% survival at day +100 and day +180, respectively. Mesoblast Limited recently submitted a Biologics License Application to the US Food and Drug Administration (FDA) for RYONCIL. The FDA agreed to fast-track consideration of the product for treating pediatric steroid-refractory aGVHD and the Oncologic Drugs Advisory Panel recommended approval; however, in October 2020 the FDA issued a Complete Response Letter requesting additional data. The specific tissue sources of MSCs are of particular interest in developing a cell product for the treatment of GVHD. Although MSCs derived from bone marrow are the most well studied, recent clinical trials have shown that MSCs derived from placental tissue, placenta-derived decidua stromal cells (DSCs), are able to suppress aGVHD, possibly with greater efficacy than BM-MSCs. Although the immunologic role of BM-MSCs in situ has not been fully elucidated, DSCs physiologically reside at the maternal-fetal interface and contribute to the immunologic barrier preventing maternal cell-mediated immunity from attacking the fetus. Considering this immunologic barrier, Ringden and colleagues propose that DSCs may have heightened immunosuppressive activity compared with MSCs harvested from other organs (eg, bone marrow), although no mechanism of action has yet to be discovered.

In a 2018 phase 1/2 clinical study (NCT02172937), DSCs isolated from term placentas were infused into patients with severe or steroid-refractory aGVHD. In the severe aGVHD group, all patients responded to treatment (48% partial; 52% complete), with a 76% 1-year survival rate when cells were thawed into 5% albumin in phosphate-buffered saline/EDTA buffer. In the steroid-refractory aGVHD group, the investigators reported 1-year survival as high as 73% compared with 20% with BM-MSCs and 3% in historical controls. Additional aGVHD clinical studies have shown that DSC infusions appeared safe and demonstrated survival rates as high as 90% at 1-year postinfusion. Despite these encouraging findings, there is only 1 published clinical study comparing DSCs with BM-MSCs; additional research and randomized trials are necessary to determine whether DSCs or MSCs are more effective. Table 2 summarizes relevant clinical trials.

Although the effect of MSCs, particular BM-MSCs, has been well studied in aGVHD, data on cGVHD are less prevalent. In a preliminary study, 4 scleroderma patients with cGVHD were infused with third-party BM-MSCs (1.0-2.0 × 10^7 cells) via intra-bone marrow infusion. Although a complete response was not observed in this trial, the investigators report a gradual improvement in symptoms over the course of 123 days, as well as an increased ratio of helper T lymphocyte 1/helper T lymphocyte 2 cells. In contrast, Peng et al reported, in a larger prospective clinical study, that 87% (N = 23) of cGVHD patients demonstrated a complete or partial response 12 months after infusion of third-party BM-MSCs (1 × 10^6/kg), most notably in skin, oral mucosa, and liver. Moreover, increased IL-10-producing CD5^+ B cells and reduced T-cell inflammatory cytokine production were observed in patients who exhibited a response to treatment, perhaps providing insight into an MSC-induced mechanism of action against cGVHD.

Altogether, these studies suggest that ex vivo–expanded BM-MSCs are safe and have the potential to treat aGVHD. In addition, MSCs derived from HLA-matched siblings or third-party donors seem to perform equally well. Interestingly, the efficacy of MSCs as a treatment for aGVHD appears to be greater in pediatric patients than in adult patients, although there is currently no experimental evidence to provide insight into the underlying mechanism of this observation. Because of its selective success in children, Prochymal is only approved for pediatrics, and RYONCIL is under FDA consideration only for pediatric indications. Although off-the-shelf MSC products have demonstrated efficacy, the level of efficacy is variable between studies, suggesting that further research is required to determine the optimal cell dosage, treatment timeline, patient age, and disease presentation to treat. Moreover, additional clinical research is needed to define the long-term effectiveness, the therapeutic mechanism of action in vivo, and the efficacy of different MSC tissue sources. Finally, placenta-derived DSCs present a promising therapy for aGVHD and should be investigated extensively in randomized clinical trials.
Table 2. A summary of reviewed MSC-based therapies used for treatment of aGVHD after allogeneic hematopoietic stem cell transplant

| MSC source | MSC dose per kg (no. doses/pt) | Age range, y (n) | Clinical context | Outcome | Phase |
|------------|-------------------------------|-----------------|-----------------|---------|-------|
| BM         | 4.9 × 10^6 (1-6)              | 0-64 (55)       | Grade II-IV aGVHD; cond: CNI/MTX/MTX/prednisolone | 69% OS; 1 OS in responders; no effect of HLA match | 2\textsuperscript{72} |
| BM         | 2 × 10^6 (6)                  | 2-66 (30)       | Grade II-IV SR aGVHD; cond: 50% myeloablative; ppx: CNI/MTX/prednisolone | 62% OS; 1 OS in pediatric vs adult responders | 1/2\textsuperscript{73} |
| BM         | 2 × 10^6 (6)                  | 5-66 (25)       | Grade II-IV SR aGVHD; cond: 56% myeloablative; ppx: CNI/MTX/prednisolone | 80% CR; 1 OS in responders, CNI/MTX/prednisolone | 2/3\textsuperscript{74} |
| BM         | 2 × 10^6 (6)                  | 0-70 (260)      | Grade II-IV SR aGVHD* | Not different from second-line placebo; 1 OR in children and pts with liver GVHD. | 3\textsuperscript{75}† |
| BM         | 2 × 10^6 (6)                  | 0-17 (55)       | Grade II-IV SR aGVHD* | Day +28 response predicted OS: 69.1% day +28 OR; 69.5% OS | 3\textsuperscript{25} |
| Placenta   | 1 × 10^6 (2)                  | 0-65 (28)       | Grade II-IV aGVHD; cond: 43% myeloablative; ppx: CNI/MTX/prednisolone | 100% OR (48% PR; 52% CR); 76% OS | 1/2\textsuperscript{26} |

All patients had GVHD organ involvement in ≥1 organ (skin, gut, liver). All MSCs were from a third-party donor and were expanded, cultured, and prepared according to good manufacturing process standards. Immune phenotyping proving MSC expression profile was performed per Horwitz et al.\textsuperscript{80}

BM, bone marrow; CNI, calcineurin inhibitor; cond, conditioning regimen; CR, complete response; MMF, mycophenolate mofetil; MTX, methotrexate; OR, overall response; OS, overall survival; ppx, GVHD prophylaxis; PR, partial response; pt(s), patient(s); SR, steroid refractory.

*Institution-specific GVHD prophylactic standard of care (majority of patients receiving CNI/MTX/prednisolone).
†Randomized clinical trial.

Tissue repair and regeneration

MSCs act directly on the immune system, and their regenerative potential could play a role in repairing tissue damage during HCT, because such injury is the first stage in the progression of aGVHD (Figure 2). MSCs are known to traffic to damaged and inflamed tissue sites, and it has been suggested that they may promote repair of damaged tissues or tissue regeneration.\textsuperscript{16,19,84} In a recent preclinical study, BALB/c mice with inflammatory bowel disease were infused with 1.0 × 10^6 MSCs and found to exhibit improved intestinal lesions; in a coinfusion of MSCs and endothelial progenitor cells, animals showed an even greater response to treatment.\textsuperscript{85} In other mouse models, MSCs have been shown to repair a variety of inflamed and damaged tissues in select diseases, including acute renal failure, peritoneal sepsis, lupus, multiple sclerosis, acute lung injury, and asthma.\textsuperscript{85}

MSC-induced tissue repair is a current avenue of research in the clinical arena. In a retrospective clinical study, 7 patients with severe late-onset hemorrhagic cystitis (HC) were infused with ≥1 dose (median 1.0 × 10^6 cells/kg) of Wharton’s jelly umbilical cord–derived MSCs, isolated from a third-party donor.\textsuperscript{87} A significant response to treatment was observed in 5 of the patients, with 3 patients having a complete response after only 1 infusion. Similarly, Hassan et al reported that HC may be successfully treated with third party BM-MSCs, noting gross hematuria receding a median of 3 days postinfusion.\textsuperscript{88}

In another clinical report, 10 patients (ages 13-64 years) developed tissue toxicity after allogeneic HCT and were treated with HLA-mismatched BM-MSC infusions.\textsuperscript{89} Seven patients developed HC (grades II-V), 2 developed pneumomediastinum, and 1 developed perforated colon and peritonitis. Gross hematuria subsided after a median of 3 days in 5 of the 7 HC patients, with the remaining 2 patients dying of multiorgan failure. Both patients with pneumomediastinum responded completely to treatment; the patient experiencing perforated colon and peritonitis initially responded to treatment, but after remission, a second infusion again reversed the disease.

Although the notion of tissue injury is an established component of GVHD pathogenesis, and the regenerative actions of MSCs have been amply demonstrated, the regenerative functions of MSCs may take on greater significance.\textsuperscript{88,90-94} Wu and Reddy have proposed the concept of tissue tolerance, the notion that a tissue’s capacity to withstand the damaging effects of the conditioning regimen contributes to the severity of aGVHD.\textsuperscript{90} MSCs may be administered to limit tissue damage and/or foster repair and regeneration, effectively increasing tissue tolerance. The idea of tissue tolerance predicts that this would mitigate the severity of GVHD. Although not yet explored, the mechanisms of MSC efficacy as prophylaxis and treatment of aGVHD may, in part, involve modulation of tissue tolerance.

Facilitating engraftment

In addition to the prevention and treatment of GVHD, MSCs may facilitate hematopoietic stem cell (HSC) engraftment by secreting hematopoietic cytokines and/or suppressing the residual host immunity, which can reject the transplanted graft. In animal systems, it has been reported that MSCs facilitate HSC engraftment and reconstituting of hematopoiesis by secreting cytokines, (eg, granulocyte-macrophage colony-stimulating factor and IL-6).\textsuperscript{95-97} Noort et al confused MSCs expanded from fetal lung tissue and umbilical cord–derived CD34 cells and noted improved bone marrow engraftment of human HSCs in NOD/SCID mice.\textsuperscript{97} MSCs have also been shown to effectively improve bone marrow HSC engraftment in an autologous mouse transplantation model.\textsuperscript{98} Recently, Yin et al demonstrated that infusions of PDGFB-transduced MSCs significantly improved human HSC engraftment in immunodeficient mice, indicating that MSCs engineered to express relevant cytokines, receptors, or growth factors may further enhance HSC engraftment.\textsuperscript{99}

In clinical studies, MSCs have also been used to improve HSC engraftment efficiency (Table 3). In the first phase 1/2 clinical trial applying MSCs to facilitate HSC engraftment, 28 breast cancer patients were given peripheral blood progenitor cells and host-expanded BM-MSC IV infusions following high-dose chemotherapy; they experienced rapid hematopoietic recovery with no observable toxicity.\textsuperscript{100} In another phase 1/2 trial, 14 children receiving haploidentical HSC transplants from relatives were given 2 infusions of donor BM-MSCs (target dose 1-5 × 10^6/kg).\textsuperscript{101} The
Table 3. Summary of reviewed MSC-based therapies aimed to improve engraftment during hematopoietic stem cell transplant in phase 1/2 clinical trials

| Graft       | MSC source | MSC dose per kg | Age range, y (n) | Clinical context                  | Outcome                                      | Reference |
|-------------|------------|-----------------|------------------|-----------------------------------|----------------------------------------------|-----------|
| PBPC (auto) | BM (auto)  | 1 to 2.2 × 10^5 | Adult (28)       | Breast cancer                     | Hematopoietic recovery                       | 100       |
| HSCT (allo) | BM (third party) | 1 to 5 × 10^5 | 1-16 (14)        | Hematol dis                       | Graft acceptance and lymphocyte recovery     | 101       |
| HSCT (auto) | BM (third party) | 2 to 5 × 10^5 | 14-60 (22)       | Hematol dis                       | 73% graft acceptance and neutrophil recovery | 102*      |
| UCBT (allo) | BM (parent) | 1 to 10 × 10^6 | 0-18 (15)        | Hematol dis                       | Hematopoietic recovery                      | 103       |
| UCBT (allo) | BM (third party) | 1 to 2.2 × 10^5 | Adult (55)       | Hematol dis                       | NE on engraftment or GVHD prevention         | 105       |
| UCBT (allo) | BM (parent) | 1 to 4.9 × 10^6 | 0-14 (13)        | Hematol dis                       | NE on engraftment or hematopoietic recovery; GVHD prevention | 104       |
| HSCT (allo) | UC (third party) | 5.0 × 10^6 | 4-31 (21)        | Hematol dis                       | Engraftment; mild GVHD                      | 108       |

MSCs have additionally been studied in the field of umbilical cord blood transplantation (UCBT). MacMillan et al reported a phase 1/2 clinical trial in which 15 pediatric leukemia patients received an UCBT, 8 of whom were simultaneously infused with BM-MSCs expanded from haploidentical parental donors. The treatment resulted in hematopoietic recovery and successful neutrophil engraftment at a median of 19 days in all 8 patients, as well as an increased survival probability relative to controls. Conversely, in another pediatric phase 1/2 trial, Bernardo et al did not observe any effect of parental BM-MSC infusions on allogeneic UCBT engraftment or hematopoietic recovery, notwithstanding that treatment was correlated with a reduced risk for aGVHD. Adult-only clinical trials testing the efficacy of MSCs at preventing UCBT graft failure and GVHD have also proved inconclusive. In sum, these findings suggest that MSC infusions used to facilitate HCT and UCBT engraftment are safe, yet overall efficacy remains controversial, especially in the adult setting.

Conclusions and future directions

MSCs are unambiguously immunosuppressive in vitro, as well as in preclinical animal models and clinical studies. However, the most appropriate clinical indications and the extent of therapeutic benefit remain to be firmly established. Although MSCs have great potential to become a standard therapeutic option for patients undergoing HCT, these cells should not be envisioned as a “magic bullet” that will rapidly and fully remedy GVHD or any other toxicity of HCT. Rather, MSCs should be considered a new agent that may have important advantages compared with current therapeutic options. The cornerstone of MSCs as a cellular therapy may be the combination of demonstrated efficacy and the outstanding clinical safety profile. Indeed, immune-suppressive activity without significant toxicity is a major advantage over pharmaceuticals, such as calcineurin inhibitors and JAK inhibitors, and could justify more widespread use in patients. Even extracorporeal photopheresis, with relatively few associated toxicities, requires placement of a dialysis-quality central venous catheter and several hours of treatment. By contrast, MSCs can be infused through peripheral IV access over minutes, not hours. Moreover, unlike many other immune-suppressive agents, there is no evidence that MSCs increase the risk of leukemic relapse or opportunistic infection.

The development of MSCs as therapy has seen many setbacks; nonetheless, recent scientific advances and well-designed clinical trials underscore the unrealized therapeutic potential and suggest that MSCs will become an important component of our armamentarium in HCT. To fulfill this prediction, 3 great challenges must be addressed. First, the basic science and complete mechanism of specific therapeutic activity must be understood. MSCs exhibit many potentially immune-modulating activities; however, it is unlikely that the cells use all possible pathways in all settings. Hence, the distinct mechanism of an explicit activity, eg, treatment of GVHD or stimulating tissue repair, must be elucidated. Such scientific knowledge will inform the development of greatly needed clinically relevant potency assays, as well as strategies to enhance MSC potency, including genetically modifying MSCs, and goals to optimize manufacturing protocols, all of which are critical elements of ultimate success. The second challenge is translational science: investigators must understand the activity of MSCs in patients. Every phase I and II clinical trial should be accompanied by an extensive battery of correlative laboratory studies to understand the impact of MSCs in human subjects. Moreover, it is especially important that these studies seek to understand why MSCs are seemingly more effective in children and whether the mechanisms can be leveraged to increase MSC efficacy in adults. The third major challenge is clinical science: well-designed adequately powered clinical trials with appropriate study populations and relevant and reasonable end points should be implemented. Only through properly designed clinical trials may optimal MSC tissue sources, cell preparations, cell dose and treatment regimen, the
appropriate patient age range, and severity of a given disorder for treatment be defined.

Sixteen years since MSCs were first reported to be effective for GVHD, the first MSC product has been recommended for approval by an FDA Advisory Committee, although the Agency requested additional data. The MSC field is entering a new era in which more sophisticated science will undoubtedly lead to new breakthroughs and establish new cellular therapies to improve outcomes of patients.

Acknowledgment
This work was funded, in part, by the National Institutes of Health, National Heart, Lung, and Blood Institute award R56 HL147867 (E.M.H.).

References

1. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic transplants of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230-247.

2. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2(2):83-92.

3. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.

4. Kern S, Eichler H, Stoewe J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24(5):1294-1301.

5. Zhang X, Yang M, Lin L, et al. Runx2 overexpression enhances osteoblastic differentiation and mineralization in adipose- derived stem cells in vitro and in vivo. Calcif Tissue Int. 2006;79(3):169-178.

6. in’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood. 2003;102(4):1548-1549.

7. Peng HH, Wang TH, Chao AS, Chang SD. Isolation and differentiation of human mesenchymal stem cells obtained from second trimester amniotic fluid; experiments at Chang Gung Memorial Hospital. Chang Gung Med J. 2007;30(5):402-407.

8. Cai J, Li W, Su H, et al. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. J Biol Chem. 2010;285(15):11227-11234.

9. Raynaud CM, Maleki M, Lis R, et al. Comprehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation. Stem Cells Int. 2012;2012:658356.

10. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015;35(2):1-e00191.

11. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther. 2009;17(6):939-946.

12. Sagar R, Walther-Jallow L, David AL, Gótherström C, Westgren M. Fetal mesenchymal stromal cells: an opportunity for prenatal cellular therapy. Stem Cells Dev. 2016;23(1):76.

13. Yue WM, Liu W, Bi YW, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, reduce neointimal formation, and enhance endothelial function in a rat vein grafting model. Stem Cells Dev. 2008;17(4):785-793.

14. Spees JL, Olson SD, Ylostalo J, et al. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc Natl Acad Sci USA. 2003;100(9):2397-2402.

15. Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let’s not overlook some essential precautions. Blood. 2007;109(8):3147-3151.

16. Wang LT, Ting CH, Yen ML, et al. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials. J Biomed Sci. 2016;23(1):76.

17. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499-3506.

18. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12(5):383-396.

19. Kramer A, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101(9):3722-3729.

20. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402.

21. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation. 2003;76(8):1208-1213.

Authorship
Contribution: A.J.B. and E.M.H. conceived and designed the review and created the figures; A.J.B. wrote the manuscript; and E.M.H. and L.P.D.-B. edited and approved the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profile: E.M.H., 0000-0002-3751-4027.

Correspondence: Edwin M. Horwitz, Emory Children’s Center, Office 424, 2015 Uppergate Dr, Atlanta, GA 30322; e-mail: edwin.horwitz@emory.edu.
23. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood*. 2002;99(10):3838-3843.

24. Keating A. Mesenchymal stromal cells: new directions. *Cell Stem Cell*. 2012;10(6):709-716.

25. Kurtzberg J, Abdel-Azim H, Carpenter P, et al; MSB-GVHD001/002 Study Group. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. *Biol Blood Marrow Transplant*. 2020;26(5):845-854.

26. Ringden O, Baygan A, Remberger M, et al. Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease. *Stem Cells Transl Med*. 2018;7(4):325-331.

27. Baygan A, Aronson-Kurttila W, Moretti G, et al. Safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis. *Front Immunol*. 2017;8:795.

28. Ringden O, Solders M, Erkers T, et al. Placenta-derived decidual stromal cells for graft-versus-host disease, hemorrhaging, and toxicity after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2015;21(2, suppl):S149.

29. Sadeghi B, Moretti G, Arnegberg F, et al. Preclinical toxicity evaluation of clinical grade placenta-derived decidua stromal cells. *Front Immunol*. 2019;10:2685.

30. Wang H-S, Hung S-C, Peng S-T, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. *Stem Cells*. 2004;22(7):1330-1337.

31. Mamidi MK, Nathan KG, Singh G, et al. Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. *J Cell Biochem*. 2012;113(10):3153-3164.

32. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells*. 2007;25(11):2739-2749.

33. Otsuru S, Hofmann TJ, Olson TS, Dominici M, Horwitz EM. Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device. *Cytotherapy*. 2013;15(2):146-153.

34. Becherucci V, Piccini L, Casamassima S, et al. Human platelet lysate in mesenchymal stromal cell culture according to a GMP grade protocol: a cell factory experience. *Stem Cell Res Ther*. 2018;9(1):124.

35. Galipeau J. Concerns arising from MSC retrieval from cryostorage and effect on immune suppressive function and pharmaceutical usage in clinical trials. *ISBT Sci Ser*. 2013;8(1):100-101.

36. Moll G, Geißler S, Catar R, et al. Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy? *Adv Exp Med Biol*. 2016;951:77-98.

37. Moll G, Alm JJ, Davies LC, et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? *Stem Cells*. 2014;32(9):2430-2442.

38. Chinnadurai R, Copland IB, Garcia MA, et al. Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFNγ licensing. *Stem Cells*. 2016;34(9):2429-2442.

39. Cruz FF, Borg ZD, Goodwin M, et al. Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice. *Stem Cells Transl Med*. 2015;4(6):615-624.

40. Oja S, Kaartinan T, Ahl M, Korhonen M, Laitinen A, Nystedt J. The utilization of freezing steps in mesenchymal stromal cell (MSC) manufacturing: potential impact on quality and cell functionality attributes. *Front Immunol*. 2019;10:1827.

41. Davies LC, Heldring N, Kadri N, Le Blanc K. Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression. *Stem Cells*. 2017;35(3):766-776.

42. Han KH, Ro H, Hong JH, et al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. *Transpl Immunol*. 2011;25(1):7-15.

43. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. *Stem Cells*. 2006;24(2):386-398.

44. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. *Blood*. 2006;107(1):367-372.

45. Le Blanc K, Tamnik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. *Scand J Immunol*. 2003;57(1):11-20.

46. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. *Transplantation*. 2003;75(3):389-397.

47. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC. Mesenchymal stem cells induce apoptosis of activated T cells. *Leukemia*. 2005;19(10):1597-1604.

48. Burr SP, Dazzi F, Garden OA. Mesenchymal stromal cells and regulatory T cells: the yin and yang of peripheral tolerance? *Immunol Cell Biol*. 2013;91(1):12-18.

49. Glennie S, Soeiro I, Dyson PJ, Lam EWF, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. *Blood*. 2005;105(7):2821-2827.

50. Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2017;23(2):211-234.

51. Sarantopoulos S, Blazar BR, Cutler C, Ritz J. B cells in chronic graft-versus-host disease. *Biol Blood Marrow Transplant*. 2015;21(1):16-23.
52. Sarantopoulos S, Ritz J. Aberrant B-cell homeostasis in chronic GVHD. Blood. 2015;125(11):1703-1707.
53. Eggenhofer E, Hoogduijn MJ. Mesenchymal stem cell-educated macrophages. Transplant Res. 2012;1(1):12.
54. Chen L, Tredget EE, Wu PYG, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008;3(4):e1886.
55. de Witte SFH, Luk F, Sierra Parraga JM, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytes. Stem Cells. 2018;36(4):602-615.
56. Galleu A, Rifo-Vasquez Y, Trenoto C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. 2017;9(416):eaam7828.
57. Luk F, de Witte SFH, Korevaar SS, et al. Inactivated mesenchymal stem cells maintain immunomodulatory capacity. Stem Cells Dev. 2016;25(18):1342-1354.
58. Hill GR, Ferrara JLM. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95(9):2754-2759.
59. Min CK. The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol. 2011;46(2):80-87.
60. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995;16(4):557-564.
61. Grégoire C, Ritacco C, Hannon M, et al. Comparison of mesenchymal stromal cells from different origins for the treatment of graft-vs.-host-disease in a humized mouse model. Front Immunol. 2019;10:619.
62. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol. 2006;176(12):7761-7767.
63. Auletta JJ, Eid SK, Wuttisarnwattana P, et al. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Stem Cells. 2015;33(2):601-614.
64. Polchert D, Sobinsky J, Douglas G, et al. IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38(6):1745-1755.
65. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21(9):1992-1999.
66. Wang L, Zhang H, Guan L, et al. Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a meta-analysis of animal models. Oncotarget. 2016;7(38):61764-61774.
67. Kalkelevik M, Larun L, Bruserud Ø, Hatfield KJ. Co-transplantation of multipotent mesenchymal stromal stem cells in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Cytotherapy. 2016;18(2):172-185.
68. Chen X, Wang C, Yin J, Xu J, Wei J, Zhang Y. Efficacy of mesenchymal stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. PLoS One. 2015;10(8):e0136991.
69. Hashmi S, Ahmed M, Murad MH, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016;3(1):e45-e52.
70. Rick M, Monaghan M, Shorr R, Kekre N, Bredeson CN, Allan DS. Heterogeneity in studies of mesenchymal stromal cells to treat or prevent graft-versus-host disease: a scoping review of the evidence. Biol Blood Marrow Transplant. 2016;22(8):1416-1423.
71. Le Blanc K, Rasmussen I, Sundberg B, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytes. Stem Cells. 2018;36(4):602-615.
72. Le Blanc K, Frassoni F, Ball L, et al; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579-1586.
73. Salmenniemi U, Ittä-Remes M, Nystedt J, et al. Good responses but high TRM in adult patients after MSC therapy for GvHD. Bone Marrow Transplant. 2017;52(4):606-608.
74. Muroi K, Miyamura K, Okada M, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016;103(2):243-250.
75. Kebrinaei P, Hayes J, Daly A, et al. A phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(5):835-844.
76. Galipeau J, Sensébœuf L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833.
77. Kurtzberg J, Prockop S, Chaudhury S, et al; MSB-275 Study Group. Study 275: updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children. Biol Blood Marrow Transplant. 2020;26(5):855-864.
78. in ’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004;22(7):1338-1345.
79. Brooke G, Rossetti T, Pelekanos R, et al. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol. 2009;144(4):571-579.
80. Horwitz EM, Le Blanc K, Dominici M, et al; International Society for Cellular Therapy. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393-395.
81. Zhou H, Guo M, Bian C, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant. 2010;16(3):403-412.
